Bénédicte Hoareau-Coudert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bénédicte Hoareau-Coudert has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alain Fischer
Hôpital Necker Enfants-Malades, AP-HP Paris, Institut Imagine, Inserm U1163, Collège de France, Paris, France
1 shared publication Alexandra Traverse-Gléhen
Université Lyon 1, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, UMR5308, ENS Lyon, France
1 shared publication- Aly Bourguiba
Sorbonne Universite, Inserm, Institut De Myologie, Centre De Recherche En Myologie - Paris (France)
1 shared publication - Amélie Vergnol
Centre de Recherche en Myologie, Sorbonne Université, INSERM UMRS 974, Institut de Myologie, 75013 Paris, France
1 shared publication - Anne Durandy
INSERM, Unité U768, Hôpital Necker Enfants-Malades, Paris, France
1 shared publication - Bruno Cadot
Centre de Recherche en Myologie - Inserm U974, Institute of Myology, Paris, France
1 shared publication
Latest Publications
- Open Access
GDF5 modulation of MuSC pool as a potential therapeutic benefit for DMD
Duchenne muscular dystrophy (DMD) is a fatal disease caused by dystrophin deficiency, leading to degeneration of the entire musculature. To improve muscle pathophysiology and gene therapy for DMD, we investigated the potential of growth differentiation factor 5 (GDF5) in the DMD mdx mouse model. We showed that the overexpression of GDF5 in the muscle improved its histology, reduced inflammation, modulated regeneration and induced the appearance of de novo fibers. We demonstrated that muscle satellite cells (MuSCs) are targeted by GDF5 which enhanced their proliferation and slowed down their myogenic commitment and finally their fusion. When combined with AAV-mediated microdystrophin gene therapy, the leading therapeutic strategy, GDF5 further increased the number of microdystrophin-positive fibers compared to gene therapy alone. These findings highlight GDF5 as a promising modulator of DMD pathology and provide the first evidence of a synergistic effect of the combination of GDF5-based intervention and AAV-microdystrophin treatment.
Open AccessGDF5 modulation of MuSC pool as a potential therapeutic benefit for DMD
Duchenne muscular dystrophy (DMD) is a fatal disease caused by dystrophin deficiency, leading to degeneration of the entire musculature. To improve muscle pathophysiology and gene therapy for DMD, we investigated the potential of growth differentiation factor 5 (GDF5) in the DMD mdx mouse model. We showed that the overexpression of GDF5 in the muscle improved its histology, reduced inflammation, modulated regeneration and induced the appearance of de novo fibers. We demonstrated that muscle satellite cells (MuSCs) are targeted by GDF5 which enhanced their proliferation and slowed down their myogenic commitment and finally their fusion. When combined with AAV-mediated microdystrophin gene therapy, the leading therapeutic strategy, GDF5 further increased the number of microdystrophin-positive fibers compared to gene therapy alone. These findings highlight GDF5 as a promising modulator of DMD pathology and provide the first evidence of a synergistic effect of the combination of GDF5-based intervention and AAV-microdystrophin treatment.
- Open Access
- 14 March 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (6)
A neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency
Here, we report on a heterozygous interferon regulatory factor 4 (IRF4) missense variant identified in three patients from a multigeneration family with hypogammaglobulinemia. Patients’ low blood plasmablast/plasma cell and naïve CD4 and CD8 T cell counts contrasted with high terminal effector CD4 and CD8 T cell counts. Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation). In B cell lines, the mutant IRF4 protein as wildtype was found to bind to known IRF4 binding motifs. The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation mass spectrometry of endogenous proteins indicated that the mutant and wildtype IRF4 proteins differed with regard to their respective sets of binding partners. Our findings highlight a novel mechanism for autosomal-dominant primary immunodeficiency through altered protein binding by mutant IRF4 at ISRE, leading to defective plasma cell differentiation.
- 14 March 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (6)
Open AccessA neomorphic mutation in the interferon activation domain of IRF4 causes a dominant primary immunodeficiency
Here, we report on a heterozygous interferon regulatory factor 4 (IRF4) missense variant identified in three patients from a multigeneration family with hypogammaglobulinemia. Patients’ low blood plasmablast/plasma cell and naïve CD4 and CD8 T cell counts contrasted with high terminal effector CD4 and CD8 T cell counts. Expression of the mutant IRF4 protein in control lymphoblastoid B cell lines reduced the expression of BLIMP-1 and XBP1 (key transcription factors in plasma cell differentiation). In B cell lines, the mutant IRF4 protein as wildtype was found to bind to known IRF4 binding motifs. The mutant IRF4 failed to efficiently regulate the transcriptional activity of interferon-stimulated response elements (ISREs). Rapid immunoprecipitation mass spectrometry of endogenous proteins indicated that the mutant and wildtype IRF4 proteins differed with regard to their respective sets of binding partners. Our findings highlight a novel mechanism for autosomal-dominant primary immunodeficiency through altered protein binding by mutant IRF4 at ISRE, leading to defective plasma cell differentiation.
- 13 March 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (6) , 1388-1391
Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing
- 13 March 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (6) , 1388-1391
Exploring the genetic landscape of HCV-related B-cell lymphomas using whole exome sequencing